Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017

Published: Mar 12, 2018

SALT LAKE CITY, March 12, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.

Fourth Quarter and Recent Corporate Highlights

  • On January 10, 2018, the Bone, Reproductive and Urologic Drugs Advisory Committee ("BRUDAC") of the U.S. Food and Drug Administration ("FDA") met to discuss the New Drug Application ("NDA") for TLANDO™, Lipocine's oral testosterone product candidate for the proposed indication of testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.
    • The Committee voted six in favor and thirteen against acceptability of overall benefit/risk profile to support approval of TLANDO as a Testosterone Replacement Therapy ("TRT").
    • Although the FDA will consider the recommendation of BRUDAC, the final decision regarding the approval of TLANDO is made by the FDA, and the recommendations by BRUDAC are non-binding.

"Although we are disappointed with the vote outcome of the BRUDAC, we believe the efficacy and safety of TLANDO are consistent with other FDA approved TRT products," said Dr. Mahesh Patel, Chairman, President, and Chief Executive Officer of Lipocine. "We are working with the FDA through the remainder of the review process and have submitted two clinical study protocols to the FDA for review. One protocol is for the conduct of an ambulatory blood pressure study and the second protocol is for the conduct of a phlebotomy study to assess the reliability of plain serum tubes for processing blood and obtaining testosterone measurements."

  • The FDA's assigned Prescription Drug User Fee Act ("PDUFA") goal date for the TLANDO NDA is May 8, 2018.
  • In January 2018, the Company received $10 million through a Loan and Security Agreement with Silicon Valley Bank.
  • The Company and the other defendants entered into a memorandum of understanding to settle the purported securities class action litigation captioned In re Lipocine Inc. Securities Litigation.

Full Year 2017 Financial Results

Lipocine reported a net loss of $21.0 million, or ($1.05) per diluted share, for the year ended December 31, 2017, compared with a net loss of $19.0 million, or ($1.04) per diluted share, for the year ended December 31, 2016.

Research and development expenses were $11.0 million during the year ended December 31, 2017, compared with $8.1 million during the year ended December 31, 2016. The increase in research and development expenses was primarily due to increased contract research organization and consultant costs TLANDO related to the Dosing Validation ("DV") and Dosing Flexibility ("DF") clinical studies, increased contract manufacturing costs for LPCN 1107 and increased outside services expenses related to the Advisory Committee meeting for TLANDO. These increases were offset by decreased contract research organization costs for LPCN 1111, a decrease in validation and commercial batch manufacturing costs for TLANDO, and a decrease in contract research organization costs for LPCN 1107.

General and administrative expenses were $10.2 million during the year ended December 31, 2017, compared with $10.4 million during the year ended December 31, 2016. The decrease in general and administrative expenses during the year ended December 31, 2017 was primarily due to decreases in pre-commercialization marketing and sales activities related to TLANDO offset by an increase related to the class-action litigation settlement liability.

As of December 31, 2017, Lipocine had cash, cash equivalents, and marketable securities of $21.5 million, compared to cash, cash equivalents, and marketable securities of $26.8 million at December 31, 2016.

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs TLANDO, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, is currently in Phase 2 testing and has been granted orphan drug designation by the FDA. For more information, please visit

Forward-Looking Statements

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine's product candidates and related clinical trials, the FDA review process relating to Lipocine's product candidates and its two new clinical study protocols, the expected timing of the FDA review process related to our resubmitted NDA for TLANDO, the impact of the BRUDAC recommendation on the FDA's decision process, the path to approvability by the FDA of Lipocine's development programs, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including that the FDA will determine there are deficiencies in our resubmitted NDA, the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.


                                                                               LIPOCINE INC. AND SUBSIDIARIES

                                                                                Consolidated Balance Sheets

                                                                                 December 31, 2017 and 2016


                                                                                                                     2017                         2016
                                                                                                                     ----                         ----


    Current assets:

                        Cash and cash
                        equivalents                                                    $3,210,749                            $5,560,716

                        securities                                                     18,257,321                            21,279,570

                        Accrued interest
                        income                                                             23,067                                38,943

                        insurance recovery                                              3,319,927                                     -

                        Prepaid and other
                        current assets                                                    408,227                               329,548

                                                    Total current assets                                       25,219,291                   27,208,777

    Property and equipment, net of accumulated depreciation

       of $1,121,080 and $1,092,710, respectively                                                             75,070                      103,440

    Other assets                                                                                              30,753                       30,753

                                                    Total assets                                              $25,325,114                  $27,342,970
                                                                                                              ===========                  ===========

                               Liabilities and Stockholders' Equity

    Current liabilities:

                       Accounts payable                                                  $598,070                              $245,915

                        settlement payable                                              4,250,000                                     -

                       Accrued expenses                                                 1,497,056                             1,080,254

                                                    Total current liabilities                                   6,345,126                    1,326,169

                                                    Total liabilities                                           6,345,126                    1,326,169
                                                                                                                ---------                    ---------

    Commitments and contingencies

    Stockholders' equity:

                        Preferred stock,
                        par value $0.0001
                        per share,

                                  zero issued and
                                  outstanding                                                     -                                    -

                        Common stock, par
                        value $0.0001 per
                        share, 100,000,000

                                  21,270,249 and

                                  issued and
                                  21,264,539 and
                                  outstanding                                                 2,127                                 1,846

                        Additional paid-in
                        capital                                                       145,423,012                           131,481,123

                        Treasury stock at
                        cost, 5,710 shares                                               (40,712)                             (40,712)

                        Accumulated other
                        comprehensive loss                                                (4,616)                              (8,493)

                       Accumulated deficit                                          (126,399,823)                         (105,416,963)

                                                    Total stockholders' equity                                 18,979,988                   26,016,801

                                                     Total liabilities and
                                                     stockholders' equity                                     $25,325,114                  $27,342,970
                                                                                                              ===========                  ===========



                                                                           LIPOCINE INC. AND SUBSIDIARIES

                                                            Consolidated Statements of Operations and Comprehensive Loss

                                                                   Years Ending December 31, 2017, 2016, and 2016


                                                                                                                                                2017                           2016                           2015
                                                                                                                                                ----                           ----                           ----

    Operating expenses:

                                                   Research and
                                                   development                                                  $11,004,281                $8,076,053                    $12,580,245

                                                   General and
                                                   administrative                                                        10,213,695                      10,382,146                      5,801,823

                                                  Restructuring costs                                                                          -                       728,635                              -

                                                   Total operating
                                                   expenses                                                              21,217,976                      19,186,834                     18,382,068

                                                  Operating loss                                                        (21,217,976)                   (19,186,834)                  (18,382,068)

    Other income, net                                                                                                                   235,816                        216,078                        173,890

                                                   Loss before
                                                   income tax
                                                   expense                                                              (20,982,160)                   (18,970,756)                  (18,208,178)

    Income tax expense                                                                                                                    (700)                         (752)                         (200)

                                                  Net loss                                                             $(20,982,860)                  $(18,971,508)                 $(18,208,378)
                                                                                                                       ============                    ============                   ============

    Basic loss per share attributable to common
     stock                                                                                   $(1.05)                $(1.04)                  $(1.11)
                                                                                              ======                  ======                    ======

    Weighted average common shares outstanding,                                                                                      20,051,934                     18,258,149                     16,470,814
                                                                                                                                     ==========                     ==========                     ==========


    Diluted loss per share attributable to common
     stock                                                                                   $(1.05)                $(1.04)                  $(1.11)
                                                                                              ======                  ======                    ======

    Weighted average common shares outstanding,
     diluted                                                                                                                         20,051,934                     18,258,149                     16,470,814
                                                                                                                                     ==========                     ==========                     ==========

    Comprehensive loss:

                                                  Net loss                                                             $(20,982,860)                  $(18,971,508)                 $(18,208,378)

                                                   Unrealized net
                                                   gain (loss) on
                                                   sale securities                                                  3,877                    24,407                       (32,900)

                                                   loss                                                                $(20,978,983)                  $(18,947,101)                 $(18,241,278)
                                                                                                                       ============                    ============                   ============





CONTACT: Morgan Brown, Executive Vice President & Chief Financial Officer, Phone: (801) 994-7383,, or Investors: Hans Vitzhum, Phone: (646) 597-6979,

View original content with multimedia:

SOURCE Lipocine Inc.


Back to news